Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Allogene Therapeutics, Inc. - Common Stock (NQ: ALLO )

1.890 -0.170 (-8.25%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Allogene Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Recap: Allogene Therapeutics Q1 Earnings
Via Benzinga
Allogene Therapeutics Reports First Quarter 2023 Financial Results and Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Announces Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Xerox, Hubbell, Spotify And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Nasdaq Composite dropping around 100 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Where Allogene Therapeutics Stands With Analysts
Via Benzinga
10 Analysts Have This to Say About Allogene Therapeutics
Via Benzinga
Allogene Therapeutics's Return On Capital Employed Insights
Via Benzinga
Allogene Therapeutics to Report First Quarter 2023 Financial Results on May 3, 2023
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Appoints Timothy Moore as Chief Technical Officer
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Presents Interim Phase 1 Data on ALLO-316 in Renal Cell Carcinoma at the American Association of Cancer Research (AACR) Annual Meeting
From Allogene Therapeutics, Inc.
Via GlobeNewswire
What 10 Analyst Ratings Have To Say About Allogene Therapeutics
Via Benzinga
7 Short-Squeeze Stocks That Could Make You Rich
Although moving against the grain presents its own distinct set of risks, these short-squeeze stocks may profit the contrarian. 
Via InvestorPlace
Consolidated Communications, CRISPR Therapeutics And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Allogene Therapeutics Announces Participation in Four Upcoming Investor Conferences
From Allogene Therapeutics, Inc.
Via GlobeNewswire
7 Short-Squeeze Stocks That Could Explode in April
Although these short-squeeze stocks attracted bearish attention justifiably, contrarian sentiment may see them jump higher. 
Via InvestorPlace
Allogene Therapeutics Publishes 2022 Annual Environmental, Social and Governance (ESG) Report
Report Highlights Company’s Mission to Democratize Patient Access to CAR T While Maintaining Focus on Employee Engagement, Sustainability and Corporate Governance 
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Short Interest Update - Monday, March 27
Although equities broadly are starting the new week higher, the most heavily shorted stocks are trading lower today. 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023
Via Benzinga
Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-316 at the American Association of Cancer Research (AACR) Annual Meeting
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds? 
Via News Direct
Topics Economy
Exposures Supply Chain
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?
By David Willey, Benzinga 
Via TheNewswire.com
Topics Economy
Exposures Supply Chain
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?
Cryoport Inc. (NASDAQ: CYRX) provides the life sciences industry with comprehensive supply chain solutions to support vital therapeutics. 
Via Benzinga
Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Announces Publication of Industry-Advancing Case Study on Chromosomal Rearrangement in Molecular Therapy
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics to Report Fourth Quarter and Year-End 2022 Financial Results on February 28, 2023
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Short Squeezes Have Returned in 2023 -- Here's Your Playbook
We haven't seen moves like these in a couple of years, so here's what investors should know. 
Via The Motley Fool
Allogene Therapeutics Presents Data on Dagger™, a Next Generation AlloCAR T™ Platform Technology
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting DLL3 as a Potential AlloCAR T™ Target for Small Cell Lung Cancer
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Why Allogene Therapeutics Shares Are Seeing Blue Skies Today
Allogene Therapeutics Inc (NASDAQ: ALLO) shares are trading higher by 13.1% to $7.76 Tuesday morning after the company announced data from its Phase 1 UNIVERSAL trial of ALLO-715 has been published in... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.